CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical trials for the treatment of breast cancer; CX-2029 that is in Phase II clinical trials for the treatment of squamous non-small cell lung cancer, head and neck squamous cell carcinoma, esophageal and gastro-esophageal junction cancers, and diffuse large B-cell lymphoma; BMS-986249, a CTLA-4 Probody therapeutic drug, which is in Phase I/II clinical trials for the treatment of metastatic melanoma; and BMS-986288, an anti-CTLA-4 Probody drug, which is in Phase I clinical trials for the treatment of solid tumors. It also develops CX-2043, a conditionally activated ADC targeting the epithelial cell adhesion molecule, as well as CX-904, a conditionally activated epidermal growth factor receptor for the treatment of solid tumor. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
CytomX Therapeutics Stock Up 3.6 %
CTMX Stock opened at $1.73 on Tuesday. The company has a fifty day moving average price of $1.63 and a 200-day moving average price of $2.42. CytomX Therapeutics has a 52-week low of $1.19 and a 52-week high of $7.53.
Analyst Upgrades and Downgrades
A number of brokerages have recently issued reports on CTMX. StockNews.com raised shares of CytomX Therapeutics from a "sell" rating to a "hold" rating in a report on Friday, August 5th. BMO Capital Markets dropped their target price on shares of CytomX Therapeutics from $9.00 to $3.00 and set a "buy" rating on the stock in a report on Thursday, July 7th. HC Wainwright cut shares of CytomX Therapeutics from a "buy" rating to a "neutral" rating in a report on Monday, July 11th. Mizuho cut shares of CytomX Therapeutics from a "buy" rating to a "neutral" rating and dropped their target price for the company from $16.00 to $4.00 in a report on Thursday, July 7th. Finally, BTIG Research decreased their price target on shares of CytomX Therapeutics from $16.00 to $8.00 and set a "buy" rating on the stock in a research note on Thursday, July 7th. Eight investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Hold" and a consensus target price of $4.89.